Kenneth C. Cassidy

592 total citations
34 papers, 474 citations indexed

About

Kenneth C. Cassidy is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Kenneth C. Cassidy has authored 34 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 12 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Kenneth C. Cassidy's work include Pharmacogenetics and Drug Metabolism (13 papers), Drug Transport and Resistance Mechanisms (5 papers) and Cancer therapeutics and mechanisms (3 papers). Kenneth C. Cassidy is often cited by papers focused on Pharmacogenetics and Drug Metabolism (13 papers), Drug Transport and Resistance Mechanisms (5 papers) and Cancer therapeutics and mechanisms (3 papers). Kenneth C. Cassidy collaborates with scholars based in United States, United Kingdom and France. Kenneth C. Cassidy's co-authors include John M. McIntosh, Dale L. Boger, Shinsuke Nakahara, Ping Yi, Jessica Rehmel, John E. Drake, Raj K. Chadha, Pratibha Mishra, Kristina Campanale and Trent L. Abraham and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

Kenneth C. Cassidy

34 papers receiving 452 citations

Peers

Kenneth C. Cassidy
David M. Ritchie United States
Nicholas Stock United States
R.E.C. Henrar Netherlands
Tonika Bohnert United States
Thomas Maduskuie United States
David M. Ritchie United States
Kenneth C. Cassidy
Citations per year, relative to Kenneth C. Cassidy Kenneth C. Cassidy (= 1×) peers David M. Ritchie

Countries citing papers authored by Kenneth C. Cassidy

Since Specialization
Citations

This map shows the geographic impact of Kenneth C. Cassidy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth C. Cassidy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth C. Cassidy more than expected).

Fields of papers citing papers by Kenneth C. Cassidy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth C. Cassidy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth C. Cassidy. The network helps show where Kenneth C. Cassidy may publish in the future.

Co-authorship network of co-authors of Kenneth C. Cassidy

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth C. Cassidy. A scholar is included among the top collaborators of Kenneth C. Cassidy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth C. Cassidy. Kenneth C. Cassidy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morse, Bridget L., Shobha Bhattachar, Xiaosu Ma, et al.. (2025). Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development. 15(1). e1594–e1594. 1 indexed citations
2.
Cuyckens, Filip, Kenneth C. Cassidy, Douglas K. Spracklin, et al.. (2024). Recommendations on the Use of Multiple Labels in Human Mass Balance Studies. Drug Metabolism and Disposition. 52(3). 153–158. 2 indexed citations
3.
Martin, Jennifer A., Boris A. Czeskis, Shweta Urva, & Kenneth C. Cassidy. (2024). Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys. European Journal of Pharmaceutical Sciences. 202. 106895–106895. 6 indexed citations
4.
Young, Graeme, Douglas K. Spracklin, Mette Lund Pedersen, et al.. (2023). Non‐Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece. Clinical Pharmacology & Therapeutics. 115(5). 931–938. 4 indexed citations
6.
Zhou, Xin, et al.. (2019). Enterohepatic circulation of glucuronide metabolites of drugs in dog. Pharmacology Research & Perspectives. 7(4). e00502–e00502. 9 indexed citations
7.
Zhou, Lian, et al.. (2019). Elimination of [14C] LY3023414 by aldehyde oxidase and CYP enzymes in humans following oral administration. Drug Metabolism and Pharmacokinetics. 34(1). S63–S63. 2 indexed citations
8.
Norman, Bryan H., Matthew J. Fisher, Boris A. Czeskis, et al.. (2018). Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury. Journal of Medicinal Chemistry. 61(5). 2041–2051. 22 indexed citations
10.
Cassidy, Kenneth C. & Ping Yi. (2017). Qualitative and quantitative prediction of human in vivo metabolic pathways in a human hepatocyte-murine stromal cell co-culture model. Xenobiotica. 48(12). 1192–1205. 4 indexed citations
11.
Zhou, Xin, et al.. (2016). Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats. Drug Metabolism and Disposition. 44(8). 1184–1192. 24 indexed citations
12.
Wickremsinhe, Enaksha, Scott M. Hynes, Malcolm I. Mitchell, et al.. (2014). Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 44(9). 827–841. 10 indexed citations
13.
Zamek‐Gliszczynski, Maciej J., Trent L. Abraham, Palaniappan Kulanthaivel, et al.. (2013). Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure. Drug Metabolism and Disposition. 41(4). 714–726. 36 indexed citations
14.
Yi, Ping, Jessica Rehmel, Kenneth C. Cassidy, et al.. (2012). Disposition and Metabolism of LY2452473, a Selective Androgen Receptor Modulator, in Humans. Drug Metabolism and Disposition. 40(12). 2354–2364. 39 indexed citations
15.
16.
Cassidy, Kenneth C., et al.. (2000). Quantitation of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide and 4-amino-3,5-dichloropyridine in rat and mouse plasma by LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 22(5). 869–877. 1 indexed citations
17.
McIntosh, John M. & Kenneth C. Cassidy. (1991). An unexpected acyloin rearrangement and oxidation of a camphor derivative. Canadian Journal of Chemistry. 69(8). 1315–1319. 5 indexed citations
18.
Howson, William, Paul W. Armstrong, Kenneth C. Cassidy, et al.. (1990). Design and synthesis of a series of glycerol-derived receptor mediated calcium entry (RMCE) blockers. European Journal of Medicinal Chemistry. 25(7). 595–602. 2 indexed citations
19.
McIntosh, John M., et al.. (1988). Diastereoselective alkylation guided by electrophile-nucleophile .pi.-interactions. The Journal of Organic Chemistry. 53(9). 1947–1952. 59 indexed citations
20.
McIntosh, John M. & Kenneth C. Cassidy. (1988). Diastereoselective alkylation of glycinates. 4. The role of the metal cation and additives. Canadian Journal of Chemistry. 66(12). 3116–3119. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026